NO993027L - Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler - Google Patents

Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler

Info

Publication number
NO993027L
NO993027L NO993027A NO993027A NO993027L NO 993027 L NO993027 L NO 993027L NO 993027 A NO993027 A NO 993027A NO 993027 A NO993027 A NO 993027A NO 993027 L NO993027 L NO 993027L
Authority
NO
Norway
Prior art keywords
pyrrolo
drugs
pyrimidinone derivatives
preparation
pyrimidinone
Prior art date
Application number
NO993027A
Other languages
English (en)
Other versions
NO993027D0 (no
Inventor
Martin Cooper
David Cheshire
David Donald
Mark Furber
Matthew Perry
Richard Harrison
Nicholas Tomkinson
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Publication of NO993027D0 publication Critical patent/NO993027D0/no
Publication of NO993027L publication Critical patent/NO993027L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nye 5-substituerte pyrrolo[3,4-d]pyrimidin-2,4-dioner som har den generelle formel (I) N-W¿Q (I) fremgangsmåter for deres fremstilling, farmasøytiske preparater inneholdende slike forbindelser, en fremgangsmåte for fremstilling av de farmasøytiske preparatene, og metoder for behandling som innebærer deres anvendelse.
NO993027A 1996-12-21 1999-06-18 Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler NO993027L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9626643.2A GB9626643D0 (en) 1996-12-21 1996-12-21 Compounds
PCT/SE1997/002157 WO1998028301A1 (en) 1996-12-21 1997-12-18 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments

Publications (2)

Publication Number Publication Date
NO993027D0 NO993027D0 (no) 1999-06-18
NO993027L true NO993027L (no) 1999-08-20

Family

ID=10804862

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993027A NO993027L (no) 1996-12-21 1999-06-18 Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler

Country Status (23)

Country Link
US (8) US6046204A (no)
EP (1) EP0946562B1 (no)
JP (1) JP2001507687A (no)
KR (1) KR20000069605A (no)
CN (1) CN1246119A (no)
AT (1) ATE215088T1 (no)
AU (1) AU717429B2 (no)
BR (1) BR9714063A (no)
CA (1) CA2275312A1 (no)
CZ (1) CZ289925B6 (no)
DE (1) DE69711430T2 (no)
EE (1) EE9900315A (no)
GB (1) GB9626643D0 (no)
HU (1) HUP0002839A3 (no)
ID (1) ID21682A (no)
IL (1) IL130538A0 (no)
IS (1) IS5082A (no)
NO (1) NO993027L (no)
NZ (1) NZ336124A (no)
PL (1) PL334228A1 (no)
SK (1) SK76699A3 (no)
TR (1) TR199901433T2 (no)
WO (1) WO1998028301A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
ATE295352T1 (de) 1999-01-15 2005-05-15 Altana Pharma Ag Phenanthridine-n-oxide mit pde-iv hemmender wirkung
US6534518B1 (en) 1999-01-15 2003-03-18 Altana Pharma Ag Polysubstituted 6-phenylphenanthridines with PDE-IV inhibiting activity
PT1147103E (pt) 1999-01-15 2005-08-31 Altana Pharma Ag Fenantridina-n-oxidos com actividade inibitoria de pde-iv
US6361486B1 (en) * 2000-02-29 2002-03-26 Agilent Technologies, Inc. Coaxial-drive centrifuge providing tilt control relative to centrifugal force
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
JP5140225B2 (ja) * 2000-08-14 2013-02-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾール
TW200407315A (en) * 2002-04-23 2004-05-16 Sankyo Co Pyrimidine derivatives
ES2546329T3 (es) * 2003-07-24 2015-09-22 Tecomet Inc. Espumas no aleatorias ensambladas
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
BRPI0711169A2 (pt) 2006-05-04 2011-08-23 Argenta Discovery Ltd tetrahidropirrolopiridinadionas e seu uso como inibidores de elastase neutrófilo humano
US8198288B2 (en) 2006-05-04 2012-06-12 Pulmagen Therapeutics (Inflammation) Limited Tetrahydropyrrolopyrimidinediones and their use in therapy
US9255099B2 (en) 2006-06-06 2016-02-09 Intra-Cellular Therapies, Inc. Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
KR20100094551A (ko) 2007-12-06 2010-08-26 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2009100403A1 (en) * 2008-02-07 2009-08-13 Neurogen Corporation Substituted aryl pyrimidinones
BRPI0922809A2 (pt) * 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
SG171777A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
EP2367431B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2011019737A1 (en) * 2009-08-10 2011-02-17 The Regents Of The University Of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
USRE48842E1 (en) 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CN108129486B (zh) * 2018-01-25 2020-06-05 华东理工大学 嘧啶酮衍生物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
GB9424842D0 (en) * 1994-12-09 1995-02-08 British Tech Group Pharmaceutical compositions

Also Published As

Publication number Publication date
NZ336124A (en) 2001-03-30
US6046204A (en) 2000-04-04
US6211368B1 (en) 2001-04-03
US20030162798A1 (en) 2003-08-28
BR9714063A (pt) 2002-01-02
CA2275312A1 (en) 1998-07-02
US6229013B1 (en) 2001-05-08
US6136974A (en) 2000-10-24
HUP0002839A3 (en) 2001-04-28
HUP0002839A2 (hu) 2001-02-28
ID21682A (id) 1999-07-08
US6166206A (en) 2000-12-26
EP0946562A1 (en) 1999-10-06
IS5082A (is) 1999-06-14
AU5580998A (en) 1998-07-17
US6306863B1 (en) 2001-10-23
KR20000069605A (ko) 2000-11-25
CN1246119A (zh) 2000-03-01
CZ289925B6 (cs) 2002-04-17
IL130538A0 (en) 2000-06-01
JP2001507687A (ja) 2001-06-12
WO1998028301A1 (en) 1998-07-02
NO993027D0 (no) 1999-06-18
SK76699A3 (en) 2000-05-16
EP0946562B1 (en) 2002-03-27
CZ220499A3 (cs) 2000-02-16
AU717429B2 (en) 2000-03-23
ATE215088T1 (de) 2002-04-15
TR199901433T2 (xx) 1999-09-21
US20020025966A1 (en) 2002-02-28
PL334228A1 (en) 2000-02-14
EE9900315A (et) 2000-02-15
GB9626643D0 (en) 1997-02-12
DE69711430D1 (de) 2002-05-02
DE69711430T2 (de) 2002-10-31

Similar Documents

Publication Publication Date Title
NO993027L (no) Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler
NO995006L (no) Nye forbindelser
NO20000311L (no) Nye forbindelser
NO20000313L (no) Nye forbindelser
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
NO20055092L (no) Substituerte pyrimidioner
ATE215954T1 (de) Pyrazolo(4,3-d)pyrimidin-derivate und diese enthaltende pharmazeutische zubereitungen
DK0624595T3 (da) Nor-galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
TR200000197T2 (tr) Yeni bileşimler
GEP20063784B (en) Optical Resolution of (1-Benzyl-4- Methylpiperidin-3-Yl) -Methylamine Enantiomers and Use Thereof for Preparation of Pyrrolo 2,3-Pyrimidine Derivatives as Protein Kinases Inhibitors
CA2272705A1 (en) Fused bicyclic pyrimidine derivatives
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
AU2002305143A1 (en) Pyrazolo'1,5-a!pyridine derivatives
IL122855A0 (en) 7H-pyrrolo [2,3-d] pyrimidine derivatives their preparation and pharmaceutical compositions containing them
YU29202A (sh) Alkilamino supstituisani biciklični azot heterocikli kao inhibitori p38 protein kinaze
NO20030381L (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
SE9702001D0 (sv) Novel compounds
DK0495982T3 (da) Bicyklisk pyrimidinderivat, fremgangsmåde til fremstilling deraf og farmaceutisk præparat omfattende dette som en aktiv bestanddel
IL104154A0 (en) Saccharin derivatives,their preparation and pharmaceutical compositions containing them
DK0404283T3 (da) 11alfa-aryl-4-estrener, fremgangsmåde til fremstilling af disse samt deres anvendelse som lægemidler
ATE242246T1 (de) (1,2,3)-triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel
NO974150L (no) 6-arylpyrazolo[3,4-d]pyrimidin-4-oner og preparater og fremgangsmåter for anvendelse derav
NO20004089L (no) Nye triazolo(4,5-d)pyrimidinforbindelser
ATE251162T1 (de) Triazolo(4,5-d)pyrimidin-verbindungen
AU1998995A (en) Substituted fused and bridged bicyclic compounds as therapeutic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application